Clinical trials in Bordeaux – page 2

1 164 clinical trials in Bordeaux, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Bordeaux at a glance

1 164

clinical trials

Research sites2

Quick filters

1 164 trials in Bordeaux

Open in trial search

Small cell lung cancer+2

Recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:BioNTech SE

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Summit Therapeutics Inc.

Contact Research Centre

Ischaemic stroke

Recruiting

A Study to Test if Rinvecalinase Alfa is Safe and Works for Treating Acute Ischemic Stroke in Patients with Moderate Stroke Severity

Investigational

A Study to Test if Rinvecalinase Alfa is Safe and Works for Treating Acute Ischemic Stroke in Patients with Moderate Stroke Severity

Investigational

France

Participants:18–64 years · 65+ years
Substances:Rinvecalinase alfa
Sponsor:Diamedica Therapeutics Inc.

Contact Research Centre

Vitiligo

Recruiting

Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

Investigational

Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

Investigational

France

Participants:0–17 years
Substances:Ruxolitinib
Sponsor:Incyte Corp.

Contact Research Centre

Bladder transitional cell carcinoma

Recruiting

Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy

Registered drugNo placebo

Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Ferring Pharmaceuticals A/S

Contact Research Centre

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Povorcitinib
Sponsor:Incyte Corp.

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

France

Participants:18–64 years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

France

Participants:18–64 years · 65+ years
Substances:Laroprovstat
Sponsor:AstraZeneca AB

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease

Recruiting

Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

Registered drugNo placebo

Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Dimeticone
Sponsor:Novartis Pharma AG

Contact Research Centre

Squamous cell carcinoma of lung+6

Recruiting

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:BNT327
Sponsor:BioNTech SE

Contact Research Centre

Chronic kidney disease+1

Recruiting

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Baxdrostat
Sponsor:AstraZeneca AB

Contact Research Centre

Bladder transitional cell carcinoma

Recruiting

Study of Nadofaragene Firadenovec for Adults with Intermediate Risk Non-Muscle Invasive Bladder Cancer

InvestigationalNo placebo

Study of Nadofaragene Firadenovec for Adults with Intermediate Risk Non-Muscle Invasive Bladder Cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Nadofaragene firadenovec
Sponsor:Ferring Pharmaceuticals A/S

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Bordeaux

What the registry says about research in the country

01 Autoimmune & Inflammatory Conditions

Innovative research focusing on psoriatic arthritis and hidradenitis suppurativa, evaluating new therapeutic combinations and treatment strategies. Studies explore the effectiveness of targeted therapies and novel approaches like fecal microbiota transplantation.

Psoriatic Arthritis Treatment
Inflammatory Skin Conditions
Myasthenia Gravis Management

Clinical trials aim to improve patient outcomes through combination therapies and innovative treatment approaches.

02 Oncology Research

Comprehensive studies investigating treatments for various cancers, including head and neck squamous cell carcinoma, endometrial cancer, and bladder cancer. Research focuses on immunotherapy combinations and targeted treatments.

Advanced Cancer Therapies
Immunotherapy Approaches
Targeted Treatment Strategies

Trials evaluate novel drug combinations and therapeutic approaches for better cancer treatment outcomes.

03 Transplant Medicine

Ground-breaking research in kidney transplantation, focusing on preventing rejection and improving long-term outcomes. Studies evaluate new immunosuppressive strategies and antibody-mediated rejection treatments.

Transplant Rejection Prevention
Immunosuppressive Therapies
Long-term Outcome Studies

Research aims to enhance transplant success rates and patient quality of life.

04 Neurological & Mental Health

Studies examining multiple sclerosis, narcolepsy, and major depressive disorder. Research investigates neuroinflammation patterns and innovative treatment approaches.

Brain Inflammation Studies
Sleep Disorders
Depression Treatment

Trials focus on understanding disease mechanisms and developing targeted therapies.

Back to France All countries